dc.contributor.author | Mwangi, D W | |
dc.contributor.author | Mukuria, J C | |
dc.contributor.author | Noguchi, A | |
dc.date.accessioned | 2013-04-22T14:00:21Z | |
dc.date.available | 2013-04-22T14:00:21Z | |
dc.date.issued | 1998 | |
dc.identifier.citation | African Journal of Health Science 1998;5(1-2):108-12 | en |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/17581004 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/16517 | |
dc.description | Journal article | en |
dc.description.abstract | A preliminary short follow-up study of Hanganutziu and Deicher (HD) antibody titre and sialic acid levels in sera from 7 patients with hepatoma was carried out. Weekly HD antibody titres were abnormal in 6 patients with titres of 4 of the 6 falling to normal in some weeks. Sialic acids levels, however were abnormal (3.830-6.82mmol/ l) compared to those of 33 normal sera (1.08-2.73 mmol/1) throughout the 8 week screening period. There was a poor correlation between the antibody tires and the sialic acid levels (r<0.50) suggesting that at some stage of malignancy, the tumour was expressing N-glycolylneuraminic acid (Neu5Gc), the epitope of HD antigens as well as shedding into circulation, excess N-acetylneuraminic acid (Neu5Gc). Neu5Gc is a tumor-associated antigen. Measurement of antibodies to this epitope have shown that the antibodies have a potential of offering an alternative method of determining tumor growth and/or metastases. A major follow-up study incorporating information on cancer type, disease stage, therapy and the immnunological status of the patient is called for. | en |
dc.language.iso | en | en |
dc.subject | Serum Hanganutziu and Deicher | en |
dc.subject | Antibody | en |
dc.subject | Total sialic acid levels | en |
dc.subject | Hepatoma patients | en |
dc.title | erum Hanganutziu and Deicher (HD) antibody and total sialic acid levels in hepatoma patients | en |
dc.type | Article | en |
local.publisher | College of Health Sciences, University of Nairobi | en |